Non-metastatic Disease
Four options, classified as nephron-sparing vs not (or surgical vs non-surgical removal):
| Nephron-sparing | Non–nephron-sparing |
|---|---|
| Endoscopic ablation/resection (ureteroscopic or percutaneous); intraluminal therapy; segmental ureterectomy | Radical nephroureterectomy with bladder cuff excision |
Nephron-sparing approaches carry a high risk of local recurrence and require vigilant follow-up.
Endoscopic ablation/resection — minimally invasive and renal-sparing, but with a high recurrence risk and residual risk of progression (imaging/biopsy under-stage). Choose retrograde (ureteroscopic) when tumour size, number, and access allow complete ablation; choose percutaneous antegrade for larger tumours, tumours hard to reach retrograde, or after prior cystectomy/diversion.
- Retrograde — lower morbidity, maintains a closed system; limited by small instruments (poorer biopsy/staging) and inability to reach some calyces (e.g. lower pole).
- Antegrade — larger instruments (more tumour removed, deeper biopsies), reaches difficult calyces, and the nephrostomy tract allows second-look nephroscopy and topical therapy; but higher morbidity, tract risks, usually inpatient, and possible (uncommon) tract seeding. A second-look nephroscopy is done 4–14 days later.
- Tumour size — <1.5 cm is optimal for ablation; ≥1.5 cm carries >80% invasive risk (ablation still possible based on experience/need for kidney sparing).
- Energy — laser (thulium, holmium, Nd:YAG) or electrocautery (small Bugbee; avoid circumferential fulguration → stricture).
- Ureteral access sheath — visualize the whole ureter first; allows repeated passage, fluid egress (lowers pelvicalyceal pressure), and lower intravesical recurrence (observational).
- Outcomes (Cutress 2012 systematic review, 34 studies) — 5-yr recurrence-free survival 13–54%, renal preservation 85%, cancer-specific survival 49–89%, OS 57–75%; outcomes worsen with grade. Repeat endoscopic evaluation within ~3 months (residual/recurrent disease is common), then at 3-month intervals until no disease.
Intraluminal therapy — indications: adjuvant after ablation, primary treatment of CIS, and primary treatment of low-grade UTUC (UGN-101).
- Adjuvant chemotherapy (thiotepa or mitomycin) — extrapolated from immediate intravesical chemo after TURBT; confirm no perforation first; delivered antegrade (nephrostomy), retrograde (ureteral catheter), or by bladder instillation with reflux via a double-J stent.
- Pelvicalyceal BCG — may be offered after complete ablation of high-risk favorable UTUC or for upper-tract CIS; imperative indications are solitary kidney, bilateral UTUC, or risk of ESRD; 6-week induction. (Foerster 2019: for CIS, RFS 84%.) The most common complication of intraluminal therapy is bacterial sepsis.
- UGN-101 (mitomycin + reverse-thermosensitive polymer; Jelmyto/Mitogel) — gels at body temperature to prolong dwell time, overcoming poor urothelial exposure. OLYMPUS (phase 3, n=71, primary/recurrent LG UTUC 5–15 mm): ~60% complete response at 3 months, ~60% of responders maintained at 12 months; adverse events common (94% any, 37% serious), 44% ureteric stenosis, 20% renal dysfunction. Carries an FDA label warning for ureteral obstruction, bone marrow suppression, and embryo-fetal toxicity.
Treatment selection by risk (AUA):
| Risk group | Preferred approach |
|---|---|
| Low-risk, favorable | Tumour ablation (preferred when feasible); chemoablation (UGN-101) if complete ablation not feasible |
| Low-risk, unfavorable | Ablation (optional for low-volume tumours or those who cannot undergo RNU) or surgical removal (RNU/segmental) |
| High-risk, favorable | Surgical removal preferred; ablation only in rare select patients (low-volume or cannot undergo RNU) |
| High-risk, unfavorable | Surgical removal. RNU with complete bladder cuff excision + lymphadenectomy is the standard of care for high-risk UTUC. Distal ureterectomy with reimplant is preferred for HR/unfavorable-LR disease confined to the lower ureter in a functional renal unit |
The surgical procedures are detailed on the Nephroureterectomy and Segmental Ureterectomy pages.
Lymph node dissection — no RCTs; recommended for high-risk UTUC (non-randomized evidence of oncologic benefit), optional for low-risk. Template by location: pyelocaliceal/proximal — ipsilateral great-vessel nodes from renal hilum to the inferior mesenteric artery (proximal ⅔ ureter to the aortic bifurcation); distal ⅓ ureter — ipsilateral pelvic nodes (at minimum obturator and external iliac).
Perioperative intravesical chemotherapy — a single dose after RNU or ureterectomy reduces bladder recurrence. ODMIT-C (n=284): a single post-op intravesical MMC dose (40 mg in 40 mL) at catheter removal reduced first-year bladder tumour risk by 11% (16% with MMC vs 27% with standard management). Gemcitabine is often preferred over MMC (risk of chemical peritonitis with extravasation).
Systemic Therapy
- Neoadjuvant chemotherapy — no RCTs, but cisplatin-based NAC should be offered for high-risk UTUC, especially when post-op eGFR is expected <60 or comorbidities would preclude post-op cisplatin (since RNU worsens renal function and cisplatin eligibility). A phase II trial (n=30, HG UTUC, 4 cycles neoadjuvant MVAC) gave a 14% pathologic complete response; a 2020 meta-analysis found pooled pCR 11% and partial response 43%. Non-cisplatin alternatives are not recommended neoadjuvantly outside trials.
- Adjuvant chemotherapy — platinum-based adjuvant chemo for advanced pathology (pT2–T4 N0–N3 M0 or pTanyN1–3 M0) not given NAC. POUT (phase 3, n=260, pT2–T4/N+): 4 cycles gemcitabine-cisplatin (gem-carbo if GFR 30–49) improved 3-year disease-free survival by 21% (71% vs 46%, HR 0.45) and metastasis-free survival; carboplatin and node-positive subgroups did worse.
- Adjuvant immunotherapy — CheckMate 274 (adjuvant nivolumab, n=709, ~20% UTUC) improved disease-free survival (21 vs 11 months overall); benefit was greater with PD-L1 ≥1%, but the UTUC subgroup hazard ratio favoured placebo. Adjuvant platinum chemotherapy is preferred over nivolumab for eligible patients who did not receive NAC; nivolumab is reserved for cisplatin-ineligible/refusing patients or high-risk pathology after NAC.
- Radiation — RNU alone gives high local control; adjuvant radiation without chemotherapy does not prevent distant failure; combined chemoradiation may have a role in advanced disease with adverse features.
Special Scenarios and Advanced Disease
- Upper-tract CIS — usually a diagnosis of exclusion (persistent positive selective cytology without endoscopic/radiographic findings). Management is not well established; most experience is with BCG via nephrostomy. Historical RNU for an isolated unilateral cytologic abnormality is no longer recommended (cytology false positives; high future bilateral risk), but observation alone is also inappropriate given repeated abnormal cytology.
- Watchful waiting/surveillance — for select patients with significant comorbidity/competing mortality risk or significant ESRD/dialysis risk from intervention; counsel about bleeding, obstruction, infection, and pain.
- Clinically node-positive (N+) — treat first with systemic therapy; consolidative RNU/ureterectomy with LND in responders.
- Distant metastatic (M+) — systemic therapy (± palliative radiation); RNU/ureterectomy is not initial therapy and has no cytoreductive benefit. MVAC (methotrexate, vinblastine, doxorubicin, cisplatin) has the highest response rate; carboplatin is substituted for renal impairment but is inferior; complete responses are rare and OS is 12–24 months.
- Unresectable localized disease — offer a clinical trial or best supportive/palliative care (radiation, systemic, endoscopic, or ablative for refractory hematuria), with multidisciplinary input.
Patient counseling — facilitate smoking cessation (smoking predicts advanced stage, recurrence, and worse mortality). Counsel on the need for endoscopic follow-up (urothelial recurrence is common regardless of approach), stricture risk with endoscopic management, the UGN-101 obstruction warning (>44%), and the risk of post-RNU CKD/dialysis. Risk factors for post-op CKD: older age, diabetes, hypertension, male sex, obesity, tobacco, larger tumour, and post-op AKI. Refer to nephrology for eGFR <45, confirmed proteinuria, diabetics with CKD, or expected post-op eGFR <30.
Self-Test
1. What are the indications for nephroureterectomy versus segmental ureterectomy? Nephroureterectomy: high-grade or ≥pT2 disease (standard of care for high-risk UTUC). Segmental ureterectomy: low-grade, low-stage tumours not removable endoscopically (size/multiplicity), or high-grade/invasive tumours when preservation of the renal unit is necessary.
2. Which trial established adjuvant chemotherapy after nephroureterectomy, and what was the result? POUT — adjuvant gemcitabine-cisplatin (gem-carbo if GFR 30–49) for pT2–T4/N+ UTUC improved 3-year disease-free survival from 46% to 71% (HR 0.45).
3. What single perioperative intervention reduces bladder recurrence after RNU, and by how much? A single post-op intravesical chemotherapy dose (ODMIT-C: MMC) reduced first-year bladder tumour risk by ~11% (16% vs 27%).